title: Protective effects of sodium thiosulfate for cisplatin-mediated ototoxicity in patients with head and neck cancer.
abstract: CONCLUSIONS
  Intra-arterial high-dose cisplatin chemoradiation (CRT-IA) with sodium thiosulfate (STS) causes relatively less severe cisplatin ototoxicity than intravenous cisplatin chemoradiation without STS (CRT-IV). The results of this study also suggest that early detection of ototoxicity is possible by testing the hearing loss at ultra-high frequencies.
  
  
  OBJECTIVE
  To investigate protective effects of STS against cisplatin ototoxicity.
  
  
  METHODS
  Between 2011 and 2013, 18 patients with head and neck carcinomas were treated with intra-arterial infusions of high-dose cisplatin (range 100-180 mg/body, mean 111 mg/body; range 2-5 courses, mean 3.6 courses) and systemic administration of cisplatin (range 66-185 mg/body, mean 130 mg/body; range 1-3 courses, mean 2.6 courses) and concurrent radiation therapy (range 60-70 Gy, mean 69 Gy). Cisplatin was neutralized by STS in CRT-IA but not in CRT-IV.
  
  
  RESULTS
  Intra-arterial infusion in the high-dose cisplatin group caused significant hearing loss at ultra-high frequencies of 10 and 12 kHz (p = 0.028, 0.039, respectively), whereas the group receiving systemic administration of cisplatin had significant hearing loss at high frequencies of 8 and 10 kHz (p = 0.016, 0.027, respectively).
authors: Otolaryngology-Head and Neck Surgery, Toyama Prefectural Hospital , Toyama.
authors: Eriko
authors: E
authors: Ishikawa
authors: Hisashi
authors: H
authors: Sugimoto
authors: Miyako
authors: M
authors: Hatano
authors: Yosuke
authors: Y
authors: Nakanishi
authors: Akira
authors: A
authors: Tsuji
authors: Kazuhira
authors: K
authors: Endo
authors: Satoru
authors: S
authors: Kondo
authors: Naohiro
authors: N
authors: Wakisaka
authors: Shigeyuki
authors: S
authors: Murono
authors: Makoto
authors: M
authors: Ito
authors: Tomokazu
authors: T
authors: Yoshizaki
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D002614:Chelating Agents / Q000627:therapeutic use*; D059248:Chemoradiotherapy; D002945:Cisplatin / Q000627:therapeutic use*; D015331:Cohort Studies; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D034381:Hearing Loss / Q000139:chemically induced / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D015994:Incidence; D007261:Infusions, Intra-Arterial; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D000077195:Squamous Cell Carcinoma of Head and Neck; D013885:Thiosulfates / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D002614:Chelating Agents; D013885:Thiosulfates; C017717:sodium thiosulfate; D002945:Cisplatin
keywords: Cisplatin; chemoradiation; head and neck squamous cell carcinoma; intra-arterial high-dose cisplatin